{
  "items": "34",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Certain Pre-Funded Warrants of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025.",
      "url": "https://www.marketscreener.com/news/certain-pre-funded-warrants-of-tango-therapeutics-inc-are-subject-to-a-lock-up-agreement-ending-on-ce7d50d3d98cf122",
      "time_published": "20251223T150923",
      "authors": [],
      "summary": "This article announces that certain Pre-Funded Warrants of Tango Therapeutics, Inc. (TNGX) are under a 61-day lock-up agreement, starting October 23, 2025, and ending on December 23, 2025. This agreement restricts executive officers, directors, and certain security holders from selling or transferring common stock or convertible securities without prior consent from Leerink Partners LLC. The news highlights a significant control measure over the company's shares.",
      "banner_image": null,
      "source": "marketscreener.com",
      "category_within_source": "General",
      "source_domain": "marketscreener.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.940464"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.845897"
        }
      ],
      "overall_sentiment_score": 0.036876,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.308336",
          "ticker_sentiment_score": "0.018861",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Certain Common Stock of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025.",
      "url": "https://www.marketscreener.com/news/certain-common-stock-of-tango-therapeutics-inc-are-subject-to-a-lock-up-agreement-ending-on-23-dec-ce7d50d3d98cf12d",
      "time_published": "20251223T000914",
      "authors": [],
      "summary": "Certain common stock of Tango Therapeutics, Inc. worth $8.700 USD are under a lock-up agreement, preventing sale or transfer for 61 days from October 23, 2025, to December 23, 2025. This lock-up applies to executive officers, directors, and certain security holders, requiring written consent from Leerink Partners LLC for any transactions. The news was published on December 22, 2025, at 07:22 pm EST.",
      "banner_image": null,
      "source": "marketscreener.com",
      "category_within_source": "General",
      "source_domain": "marketscreener.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.924111"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.843682"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.722123"
        }
      ],
      "overall_sentiment_score": 0.027748,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.014717",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of \"Moderate Buy\" from Analysts",
      "url": "https://www.marketbeat.com/instant-alerts/tango-therapeutics-inc-nasdaqtngx-receives-consensus-recommendation-of-moderate-buy-from-analysts-2025-12-21/",
      "time_published": "20251221T110935",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Tango Therapeutics, Inc. (NASDAQ:TNGX) has received a consensus \"Moderate Buy\" rating from analysts, with an average 1-year price target of $13.00. This is based on ratings from eight research firms, including six \"buy\" ratings, one \"hold,\" and one \"sell.\" The company recently reported better-than-expected earnings and revenue but still shows negative profitability metrics and is forecast to post a negative full-year EPS.",
      "banner_image": "https://www.marketbeat.com/logos/tango-therapeutics-inc-logo-1200x675.png?v=20210816052814",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.940937"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.815225"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.743352"
        }
      ],
      "overall_sentiment_score": 0.277073,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.271846",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "5 Biotech Stocks to Watch for Potential Upside",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/ANIP/pressreleases/36676124/5-biotech-stocks-to-watch-for-potential-upside/",
      "time_published": "20251218T060905",
      "authors": [
        "Zacks Investment Research",
        "Inc."
      ],
      "summary": "The biotech industry is projected to perform strongly in 2025, driven by continuous innovation, new drug approvals, and a significant increase in M&A activities, particularly focusing on AI-driven drug discovery. Despite the sector's inherent volatility and high R&D costs, its critical role in advanced medical treatments and breakthrough technologies, along with a favorable Zacks Industry Rank, suggest a bright outlook. Biotech companies like Arcutis Biotherapeutics (ARQT), Amicus Therapeutics (FOLD), ANI Pharmaceuticals (ANIP), Tango Therapeutics (TNGX), and Pacira Biosciences (PCRX) are highlighted as positioned to outperform.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.920045"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.808311"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.709406"
        }
      ],
      "overall_sentiment_score": 0.406998,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.905747",
          "ticker_sentiment_score": "0.417598",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference",
      "url": "https://www.globenewswire.com/news-release/2025/12/17/3206852/0/en/tango-therapeutics-to-participate-in-44th-annual-j-p-morgan-healthcare-conference.html",
      "time_published": "20251217T170905",
      "authors": [],
      "summary": "Tango Therapeutics (NASDAQ: TNGX) will participate in the 44th Annual J.P. Morgan Healthcare Conference. Barbara Weber, M.D., President and CEO, is scheduled to deliver a corporate presentation on January 14, 2026. A live webcast and archived replay will be available on the company\u2019s website.",
      "banner_image": "https://ml.globenewswire.com/media/YTg1ZTNiYjctZGMzZS00OWQ3LWJhOGUtYzFlMzA0YTg1YzcyLTEyMjA5ODQtMjAyNS0xMi0xNy1lbg==/tiny/Tango-Therapeutics-Sub-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909641"
        },
        {
          "topic": "finance",
          "relevance_score": "0.736307"
        }
      ],
      "overall_sentiment_score": 0.132052,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.141908",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.627776",
          "ticker_sentiment_score": "0.142435",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference",
      "url": "https://www.globenewswire.com/news-release/2025/12/17/3206852/0/en/Tango-Therapeutics-to-Participate-in-44th-Annual-J-P-Morgan-Healthcare-Conference.html",
      "time_published": "20251217T120900",
      "authors": [],
      "summary": "Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that its President and CEO, Barbara Weber, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be webcast live on the company's website and a replay will be available for 90 days. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer.",
      "banner_image": "https://ml.globenewswire.com/media/YTg1ZTNiYjctZGMzZS00OWQ3LWJhOGUtYzFlMzA0YTg1YzcyLTEyMjA5ODQtMjAyNS0xMi0xNy1lbg==/tiny/Tango-Therapeutics-Sub-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924509"
        },
        {
          "topic": "finance",
          "relevance_score": "0.724573"
        }
      ],
      "overall_sentiment_score": 0.111736,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.135688",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference",
      "url": "https://finance.yahoo.com/news/tango-therapeutics-participate-44th-annual-120000780.html",
      "time_published": "20251217T070000",
      "authors": [
        "NULL"
      ],
      "summary": "Tango Therapeutics will participate in the 44th Annual J.P. Morgan Healthcare Conference, with President and CEO Barbara Weber, M.D., scheduled to deliver a corporate presentation on January 14, 2026. The presentation will be webcast live and archived on the company's investor relations website. Tango Therapeutics focuses on discovering novel drug targets and developing precision medicines for cancer treatment using synthetic lethality.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.906134"
        },
        {
          "topic": "finance",
          "relevance_score": "0.704029"
        }
      ],
      "overall_sentiment_score": 0.020861,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.344046",
          "ticker_sentiment_score": "0.028711",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Tango Therapeutics (TNGX) Overvalued After a 200% One-Year Surge? A Fresh Look at Its Pricing",
      "url": "https://finance.yahoo.com/news/tango-therapeutics-tngx-overvalued-200-200508582.html",
      "time_published": "20251215T180911",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Tango Therapeutics (TNGX) stock has surged roughly 200% over the past year due to investor reassessment of its oncology pipeline, making its current valuation significantly higher than industry averages. The company trades at a price-to-sales multiple of 18.9x, far exceeding the US Biotechs industry average of 12.1x and a fair estimated P/S of 1.4x, suggesting it may be overvalued unless future clinical milestones and revenue growth significantly improve. Investors are paying a steep premium in anticipation of future success rather than current profits.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/HkW.of1x4JHpvrHVFxKcTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwODtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2021-03/7d6207c0-7d34-11eb-bbee-858baefb8682",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.921497"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.825787"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.719237"
        }
      ],
      "overall_sentiment_score": 0.001994,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.041739",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics (NASDAQ:TNGX) Raised to Buy at Wall Street Zen",
      "url": "https://www.marketbeat.com/instant-alerts/tango-therapeutics-nasdaqtngx-raised-to-buy-at-wall-street-zen-2025-12-13/",
      "time_published": "20251213T170900",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Wall Street Zen upgraded Tango Therapeutics (NASDAQ:TNGX) from \"hold\" to \"buy\" after the company reported an earnings beat with $0.13 EPS against a $0.01 consensus and $53.8M in revenue versus $41.35M expected. Despite this, the company remains unprofitable, and analysts project a negative EPS of -1.19 for the current fiscal year. Insider selling has occurred, with major shareholder Rock Ventures selling 477,401 shares and other insiders selling approximately 1.34 million shares over the last three months, while institutional investors hold nearly 79% of the company's stock.",
      "banner_image": "https://www.marketbeat.com/logos/tango-therapeutics-inc-logo-1200x675.png?v=20210816052814",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.901882"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.817814"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.738585"
        }
      ],
      "overall_sentiment_score": 0.284208,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.281299",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Stempoint Capital LP Acquires Shares of 208,800 Tango Therapeutics, Inc. $TNGX",
      "url": "https://www.marketbeat.com/instant-alerts/filing-stempoint-capital-lp-acquires-shares-of-208800-tango-therapeutics-inc-tngx-2025-12-10/",
      "time_published": "20251213T160924",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Stempoint Capital LP has acquired a new position in Tango Therapeutics, purchasing 208,800 shares valued at approximately $1.07 million, increasing institutional ownership to 78.99%. Insider Rock Ventures recently sold 500,000 shares, bringing insider ownership to 7.50%. The company has an average analyst rating of \"Moderate Buy\" with a $13 price target, and it recently surpassed revenue and EPS estimates despite remaining unprofitable.",
      "banner_image": "https://www.marketbeat.com/logos/tango-therapeutics-inc-logo-1200x675.png?v=20210816052814",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.916219"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.747601"
        },
        {
          "topic": "finance",
          "relevance_score": "0.607141"
        }
      ],
      "overall_sentiment_score": 0.347415,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.992089",
          "ticker_sentiment_score": "0.319051",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect?",
      "url": "https://finviz.com/news/248469/can-tango-therapeutics-tngx-climb-3728-to-reach-the-level-wall-street-analysts-expect",
      "time_published": "20251209T190942",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Tango Therapeutics (TNGX) closed at $9.63, gaining 22.4% over the past four weeks, with a mean price target of $13.22 indicating a 37.3% upside potential. Despite the common skepticism around analyst price targets, a strong agreement among analysts and positive earnings estimate revisions suggest potential upside for TNGX, which also holds a Zacks Rank #2 (Buy). While price targets should be treated with skepticism, the consistency in analyst revisions and the Zacks Rank indicate a favorable outlook for the stock.",
      "banner_image": "https://finviz.com/gfx/nic2x2.gif",
      "source": "Finviz",
      "category_within_source": "General",
      "source_domain": "Finviz",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.938217"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.806349"
        }
      ],
      "overall_sentiment_score": 0.412266,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.413894",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by XTX Topco Ltd",
      "url": "https://www.marketbeat.com/instant-alerts/filing-tango-therapeutics-inc-tngx-stock-holdings-trimmed-by-xtx-topco-ltd-2025-12-09/",
      "time_published": "20251209T140904",
      "authors": [
        "MarketBeat"
      ],
      "summary": "XTX Topco Ltd significantly reduced its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 66.8% in Q2, selling 112,339 shares. Despite this, analysts have a \"Moderate Buy\" consensus rating with an average target price of $13.00, and the company recently surpassed quarterly earnings and revenue estimates. Insider selling has also occurred, with Rock Ventures Iv L.P. Third selling 500,000 shares for $4.01 million.",
      "banner_image": "https://www.marketbeat.com/logos/tango-therapeutics-inc-logo-1200x675.png?v=20210816052814",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.935994"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.810589"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.906341"
        }
      ],
      "overall_sentiment_score": 0.121799,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.133939",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Vivo Capital LLC Purchases Shares of 600,000 Tango Therapeutics, Inc. $TNGX",
      "url": "https://www.marketbeat.com/instant-alerts/filing-vivo-capital-llc-purchases-shares-of-600000-tango-therapeutics-inc-tngx-2025-12-09/",
      "time_published": "20251209T140904",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Vivo Capital LLC recently acquired 600,000 shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) for approximately $3.07 million, establishing a 0.54% stake in the company. Institutional investors collectively own about 78.99% of Tango Therapeutics, which has received a \"Moderate Buy\" consensus rating from analysts with an average price target of $13. The company outperformed revenue expectations in its last quarterly earnings but remains unprofitable with a negative return on equity and net margin.",
      "banner_image": "https://www.marketbeat.com/logos/tango-therapeutics-inc-logo-1200x675.png?v=20210816052814",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.921200"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.831107"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.732622"
        }
      ],
      "overall_sentiment_score": 0.166346,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.296986",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GOOGL",
          "relevance_score": "0.554727",
          "ticker_sentiment_score": "0.131592",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.581786",
          "ticker_sentiment_score": "0.140654",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%",
      "url": "https://www.sahmcapital.com/news/content/subdued-growth-no-barrier-to-tango-therapeutics-inc-nasdaqtngx-with-shares-advancing-32-2025-12-05",
      "time_published": "20251207T180846",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Tango Therapeutics, Inc. (NASDAQ:TNGX) shares have surged 32% in the last month and 192% over the last year, leading to a high price-to-sales (P/S) ratio of 20x compared to an industry average of 12.1x. Despite impressive past revenue growth of 53% in the last year, analysts project a modest 0.3% annual growth for the next three years, significantly lower than the industry's 128% forecast. The article questions whether the current high P/S ratio is justified given the subdued future growth outlook.",
      "banner_image": "https://r.sahmcapital.com/fe/hs-sa-web-nuxt-www-alsahm/img/logo.456360b.png",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.910678"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.800382"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.709742"
        }
      ],
      "overall_sentiment_score": -0.243715,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.240566",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/subdued-growth-no-barrier-to-tango-therapeutics-inc-nasdaqtn-1",
      "time_published": "20251206T050136",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Tango Therapeutics (NASDAQ:TNGX) shares have seen a 32% gain in the last month, contributing to a 192% increase over the past year. Despite this strong performance, the company's price-to-sales (P/S) ratio of 20x is significantly higher than the industry average, as its revenue growth has been less than most competitors, and future growth is projected at only 0.3% per annum against an industry forecast of 128%. This discrepancy suggests that investors might be overly optimistic about a turnaround, potentially setting themselves up for disappointment if the P/S ratio adjusts to align with the more subdued growth outlook from analysts.",
      "banner_image": "https://images.simplywall.st/asset/chart/424111353-ps-multiple-vs-industry-1-dark-2/1764930815398",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.930727"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.816552"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.709232"
        }
      ],
      "overall_sentiment_score": 0.112174,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.145413",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Stifel Initiates Coverage of Tango Therapeutics (TNGX) with Buy Recommendation",
      "url": "https://www.nasdaq.com/articles/stifel-initiates-coverage-tango-therapeutics-tngx-buy-recommendation",
      "time_published": "20251205T050136",
      "authors": [
        "George Maybach"
      ],
      "summary": "Stifel has initiated coverage of Tango Therapeutics (NASDAQ:TNGX) with a Buy recommendation. The average one-year price target for Tango Therapeutics is $12.50/share, suggesting a 30.56% upside from its latest closing price. Institutional ownership in TNGX has increased, though the put/call ratio indicates a bearish outlook among some investors.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.905878"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.843869"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.740196"
        }
      ],
      "overall_sentiment_score": 0.334373,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.924555",
          "ticker_sentiment_score": "0.304545",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target",
      "url": "https://www.investing.com/news/analyst-ratings/stifel-initiates-tango-therapeutics-stock-with-buy-rating-15-price-target-93CH-4389577",
      "time_published": "20251204T050136",
      "authors": [
        "Investing.com"
      ],
      "summary": "Stifel has initiated coverage on Tango Therapeutics Inc. (NASDAQ:TNGX) with a Buy rating and a $15 price target, citing the potential of its lead clinical candidate, vopimetostat, as a best-in-class PRMT5 inhibitor. The firm projects vopimetostat could become the standard of care in second-line pancreatic cancer treatment, with a Phase 3 trial anticipated in 2026. This positive outlook is supported by Tango's strong financial position and recent successful financing activities.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949908"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.827632"
        },
        {
          "topic": "finance",
          "relevance_score": "0.738649"
        }
      ],
      "overall_sentiment_score": 0.638599,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.618186",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages",
      "url": "https://www.marketbeat.com/instant-alerts/tango-therapeutics-inc-nasdaqtngx-given-consensus-recommendation-of-moderate-buy-by-brokerages-2025-11-26/",
      "time_published": "20251201T050136",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Tango Therapeutics, Inc. (NASDAQ:TNGX) has received a consensus \"Moderate Buy\" rating from seven brokerages, with an average 12-month price target of $12.50. Despite reporting stronger-than-expected Q3 earnings and revenue, the company remains unprofitable, with analysts forecasting a full-year EPS of approximately -$1.19. Institutional ownership is high at nearly 79%, even as insiders have recently sold over 2 million shares.",
      "banner_image": "https://www.marketbeat.com/logos/tango-therapeutics-inc-logo-1200x675.png?v=20210816052814",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.936323"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.894804"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.765135"
        }
      ],
      "overall_sentiment_score": 0.215356,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.953553",
          "ticker_sentiment_score": "0.229603",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference",
      "url": "https://www.globenewswire.com/news-release/2025/11/26/3195002/0/en/Tango-Therapeutics-to-Participate-in-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html",
      "time_published": "20251201T050136",
      "authors": [
        "NULL"
      ],
      "summary": "Tango Therapeutics announced that Dr. Adam Crystal, President of Research & Development, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 1:30 PM ET. A live webcast and subsequent replay will be available on the company's investor relations website. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer using the principle of synthetic lethality.",
      "banner_image": "https://ml.globenewswire.com/media/NzNkZTY2M2EtN2Q0Zi00MTc0LWIwMTgtMmY2NzczMTcyYmRlLTEyMjA5ODQtMjAyNS0xMS0yNi1lbg==/tiny/Tango-Therapeutics-Sub-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.121633,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.143567",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference",
      "url": "https://finance.yahoo.com/news/tango-therapeutics-participate-piper-sandler-120000797.html",
      "time_published": "20251127T190942",
      "authors": [],
      "summary": "Tango Therapeutics announced that Adam Crystal, M.D., Ph.D., President of Research & Development, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3. A live webcast and replay of the event will be available on the company's website. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer treatment.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.920229"
        }
      ],
      "overall_sentiment_score": 0.026011,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.338873",
          "ticker_sentiment_score": "0.021645",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy (TNGX)",
      "url": "https://seekingalpha.com/article/4846693-tango-therapeutics-prmt5-inhibitor-vopimetostat-approaches-pivotal-testing-buy",
      "time_published": "20251124T050136",
      "authors": [
        "Terry Chrisomalis"
      ],
      "summary": "Tango Therapeutics, Inc. (TNGX) receives a Buy rating due to the strong progress of its lead PRMT5 inhibitor, vopimetostat, for MTAP-deleted cancers. Positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer showed improved progression-free survival and objective response rates. A pivotal trial for vopimetostat is planned for 2026, with further expansion studies into other indications like MTAP-deleted lung cancer.",
      "banner_image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238217382/image_2238217382.jpg?io=getty-c-w630",
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.942500"
        }
      ],
      "overall_sentiment_score": 0.478932,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.462477",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Tango Therapeutics launches $100M at-the-market stock offering",
      "url": "https://www.msn.com/en-us/money/markets/tango-therapeutics-launches-100m-at-the-market-stock-offering/ar-AA1QTpmV?ocid=finance-verthp-feeds",
      "time_published": "20251124T050136",
      "authors": [],
      "summary": "Tango Therapeutics has announced an \"at-the-market\" offering to sell up to $100 million of its common stock. This financial move allows the company to raise capital opportunistically, leveraging market conditions for its shares.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.916559"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.749030"
        }
      ],
      "overall_sentiment_score": -0.24703,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.217340",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights",
      "url": "https://www.globenewswire.com/news-release/2025/11/04/3180438/0/en/Tango-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Highlights.html",
      "time_published": "20251104T090000",
      "authors": [],
      "summary": "Tango Therapeutics announced its Q3 2025 financial results and business highlights. Key updates include positive clinical data for vopimetostat (TNG462) in pancreatic cancer, with a planned pivotal trial launch in 2026, and a strong financial position with $225 million in recent financing extending its cash runway into 2028. The company also reported progress in other pipeline candidates, including TNG456 achieving Orphan Drug Designation and promising early data for TNG260 in STK11 mutant lung cancer.",
      "banner_image": "https://ml.globenewswire.com/media/MTA0NGM5NzktMTM1Yy00ZDYxLWEzZTItOGMwYjFjNTgwNjZjLTEyMjA5ODQtMjAyNS0xMS0wNC1lbg==/tiny/Tango-Therapeutics-Sub-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.936401"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.904562"
        }
      ],
      "overall_sentiment_score": 0.235865,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.315547",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.641993",
          "ticker_sentiment_score": "0.139552",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics Hits Day High with 18.63% Surge in Stock Price - Markets Mojo",
      "url": "https://www.marketsmojo.com/news/stocks-in-action/tango-therapeutics-hits-day-high-with-1863-surge-in-stock-price-3620275",
      "time_published": "20251018T205422",
      "authors": [],
      "summary": "Tango Therapeutics (TNGX) saw its stock price surge by 18.63% on October 13, 2025, reaching an intraday high of USD 8.59, and has reported significant gains over the past week, month, and year-to-date. Despite impressive stock performance, the company faces financial challenges including a net profit decline of 2.57%, negative EBITDA, and a return on equity of -107.86%, indicative of a risky position within the competitive biotechnology sector.",
      "banner_image": "https://i.marketsmojo.com/newsimg/2025/10/TangoTherapeuti_priceRelatedfactors_3620275.png",
      "source": "Markets Mojo",
      "category_within_source": "General",
      "source_domain": "Markets Mojo",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.923987"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.922382"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.831650"
        }
      ],
      "overall_sentiment_score": 0.018865,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.303138",
          "ticker_sentiment_score": "0.047933",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics stock hits 52-week high at 9.69 USD By Investing.com - Investing.com Philippines",
      "url": "https://ph.investing.com/news/company-news/tango-therapeutics-stock-hits-52week-high-at-969-usd-93CH-2042231",
      "time_published": "20251016T232541",
      "authors": [
        "Investing.com"
      ],
      "summary": "This article from Investing.com Philippines reports that Tango Therapeutics stock reached a new 52-week high of $9.69 USD. The body of the article appears to have encountered a client-side application error, preventing further details from being displayed.",
      "banner_image": null,
      "source": "Investing.com Philippines",
      "category_within_source": "General",
      "source_domain": "Investing.com Philippines",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944863"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.802844"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.640825"
        }
      ],
      "overall_sentiment_score": 0.044272,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.303508",
          "ticker_sentiment_score": "0.037562",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics stock hits 52-week high at 9.69 USD By Investing.com - Investing.com Nigeria",
      "url": "https://ng.investing.com/news/company-news/tango-therapeutics-stock-hits-52week-high-at-969-usd-93CH-2149854",
      "time_published": "20251016T193510",
      "authors": [
        "Investing.com"
      ],
      "summary": "The Investing.com Nigeria article reports that Tango Therapeutics stock reached a new 52-week high of $9.69 USD. However, the article itself appears to be experiencing a client-side application error, preventing the full content from loading.",
      "banner_image": null,
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.904520"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.602730"
        }
      ],
      "overall_sentiment_score": 0.049314,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.343556",
          "ticker_sentiment_score": "0.020727",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics stock hits 52-week high at 9.69 USD By Investing.com - Investing.com Canada",
      "url": "https://ca.investing.com/news/company-news/tango-therapeutics-stock-hits-52week-high-at-969-usd-93CH-4251085",
      "time_published": "20251016T164434",
      "authors": [
        "Investing.com"
      ],
      "summary": "The article reports that Tango Therapeutics stock reached a new 52-week high of $9.69 USD. The Investing.com Canada page, however, encountered an application error when attempting to load the full content.",
      "banner_image": null,
      "source": "Investing.com Canada",
      "category_within_source": "General",
      "source_domain": "Investing.com Canada",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.908655"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.542295"
        }
      ],
      "overall_sentiment_score": 0.044343,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.331263",
          "ticker_sentiment_score": "0.013311",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics Hits New 52-Week High of $9.11, Showcasing Strong Growth - Markets Mojo",
      "url": "https://www.marketsmojo.com/news/stocks-in-action/tango-therapeutics-hits-new-52-week-high-of-911-showcasing-strong-growth-3622842",
      "time_published": "20251015T224144",
      "authors": [],
      "summary": "Tango Therapeutics, a small-cap biotechnology company, reached a new 52-week high of $9.11 on October 14, 2025, reflecting a significant 21.51% gain over the past year. Despite this strong stock performance, the company faces financial challenges including a negative return on equity and a high price-to-book ratio, operating in a highly competitive sector.",
      "banner_image": "https://i.marketsmojo.com/newsimg/2025/10/TangoTherapeuti_priceRelatedfactors_3622842.png",
      "source": "Markets Mojo",
      "category_within_source": "General",
      "source_domain": "Markets Mojo",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.844838"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.747146"
        }
      ],
      "overall_sentiment_score": 0.048614,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.332254",
          "ticker_sentiment_score": "0.048148",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program",
      "url": "https://www.biospace.com/press-releases/tango-therapeutics-reports-positive-tng462-clinical-data-and-provides-update-on-prmt5-development-program",
      "time_published": "20241106T000000",
      "authors": [],
      "summary": "Tango Therapeutics announced positive clinical data for TNG462, showcasing durable activity across multiple tumor types, including NSCLC and pancreatic cancer, and moving it into full development with combination studies planned for 2025. The company is also introducing TNG456, a next-generation brain-penetrant PRMT5 inhibitor for glioblastoma and other solid tumors, while halting enrollment for TNG908 to focus resources on the other two candidates. These strategic shifts aim to enhance treatment options for MTAP-deleted cancers, including a new clinical collaboration with Revolution Medicines.",
      "banner_image": null,
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916857"
        }
      ],
      "overall_sentiment_score": 0.273548,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.402418",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MRK",
          "relevance_score": "0.644320",
          "ticker_sentiment_score": "0.126697",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tango Therapeutics to Participate in Upcoming Investor Conferences",
      "url": "https://www.stocktitan.net/news/TNGX/tango-therapeutics-to-participate-in-upcoming-investor-wbtlfw9wpflo.html",
      "time_published": "20240828T070000",
      "authors": [],
      "summary": "Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that its President and CEO, Barbara Weber, M.D., will participate in two upcoming investor conferences in September: the 2024 Wells Fargo Healthcare Conference and the 2024 Cantor Global Healthcare Conference. The presentations will be webcast live and archived on the company's website. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision cancer medicines.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949769"
        },
        {
          "topic": "finance",
          "relevance_score": "0.719620"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.619724"
        }
      ],
      "overall_sentiment_score": 0.148201,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.139986",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Medivir\u00b4s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program",
      "url": "https://www.stocktitan.net/news/TNGX/medivir-s-licensee-tango-therapeutics-has-discontinued-development-ui6gkcoz9aet.html",
      "time_published": "20240523T091800",
      "authors": [],
      "summary": "Medivir announced that its licensee, Tango Therapeutics, has discontinued the clinical development of TNG348, a USP1 inhibitor for BRCA1/2-mutant and HRD+ cancers, due to toxicity observed in phase 1/2 trials. Despite this setback, Medivir reaffirmed its focus on its lead program, fostroxacitabine bralpamide (fostrox), targeting primary liver cancer. The company is accelerating efforts to initiate a pivotal phase 2b study for fostrox, which has the potential to secure market approval for HCC patients not responding to current first-line treatments, a market estimated at $2.5 billion annually by 2028.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.938841"
        }
      ],
      "overall_sentiment_score": -0.639483,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.648500",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Tango drops USP1 inhibitor over liver toxicity in patients during phase 1 trial",
      "url": "https://www.fiercebiotech.com/biotech/tango-drops-usp1-inhibitor-over-liver-toxicity-patients-during-phase-1-trial",
      "time_published": "20240523T081100",
      "authors": [
        "James Waldron"
      ],
      "summary": "Tango Therapeutics has discontinued the development of its USP1 inhibitor, TNG348, due to liver toxicity observed in patients during a phase 1/2 clinical trial. Grade 3/4 liver function abnormalities were reported in patients who continued treatment for over eight weeks. The company will now focus its resources on its remaining pipeline, including its PRMT5 program with lead candidate TNG908.",
      "banner_image": null,
      "source": "Fierce Biotech",
      "category_within_source": "General",
      "source_domain": "Fierce Biotech",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": -0.181411,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.633397",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "MRK",
          "relevance_score": "0.606645",
          "ticker_sentiment_score": "-0.127981",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.617154",
          "ticker_sentiment_score": "0.219335",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "VRK1 Is a Synthetic\u2013Lethal Target in VRK2-Deficient Glioblastoma",
      "url": "https://aacrjournals.org/cancerres/article/82/21/4044/709959/VRK1-Is-a-Synthetic-Lethal-Target-in-VRK2",
      "time_published": "20221102T185633",
      "authors": [
        "Julie A. Shields",
        "Samuel R. Meier",
        "Madhavi Bandi",
        "Erin E. Mulkearns-Hubert",
        "Nicole Hajdari",
        "Maria Dam Ferdinez",
        "Justin L. Engel",
        "Daniel J. Silver",
        "Binzhang Shen",
        "Wenhai Zhang",
        "Christopher G. Hubert",
        "Kelly Mitchell",
        "Sajina Shakya",
        "Shan-Chuan Zhao",
        "Alborz Bejnood",
        "Minjie Zhang",
        "Robert Tjin Tham Sjin",
        "Erik Wilker",
        "Justin D. Lathia",
        "Jannik N. Andersen",
        "Yingnan Chen",
        "Fang Li",
        "Barbara Weber",
        "Alan Huang",
        "Natasha Emmanuel"
      ],
      "summary": "This research identifies VRK1 as a synthetic-lethal target in glioblastoma (GBM) cells that are deficient in VRK2, a condition often caused by promoter methylation in two-thirds of GBMs. Knockdown of VRK1 in VRK2-deficient cells leads to impaired nuclear envelope formation, G2-M cell-cycle arrest, and DNA damage, ultimately inhibiting tumor growth both in vitro and in patient-derived xenograft models. The study suggests that inhibiting VRK1 kinase activity could be a promising therapeutic strategy for VRK2-methylated GBM, an aggressive and hard-to-treat form of brain cancer.",
      "banner_image": null,
      "source": "aacrjournals.org",
      "category_within_source": "General",
      "source_domain": "aacrjournals.org",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.491445,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.496865",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies",
      "url": "https://www.stocktitan.net/news/TNGX/tango-therapeutics-debuts-as-publicly-traded-precision-oncology-nvt9ghft5s23.html",
      "time_published": "20210810T090000",
      "authors": [],
      "summary": "Tango Therapeutics has completed its business combination with BCTG Acquisition Corp., becoming a publicly traded company listed on Nasdaq under the ticker TNGX. This transaction provides Tango with a substantial cash position of approximately $515 million, which includes $342 million in gross proceeds, to advance its precision oncology therapies. The company aims to develop novel treatments for genetically-defined cancer patient populations, with its lead program focusing on a synthetic lethal inhibitor of PRMT5 for MTAP-deleted cancers.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "1.000000"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.044058,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.348125",
          "ticker_sentiment_score": "0.035049",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}